Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 4,700 shares, a decline of 27.7% from the May 31st total of 6,500 shares. Based on an average daily volume of 18,600 shares, the short-interest ratio is presently 0.3 days. Currently, 0.6% of the company’s shares are short sold.
Addex Therapeutics Price Performance
Addex Therapeutics stock opened at $8.22 on Monday. The firm has a market capitalization of $8.71 million, a P/E ratio of -0.48 and a beta of 1.78. Addex Therapeutics has a 1-year low of $5.00 and a 1-year high of $27.90. The company’s 50-day moving average is $9.43 and its 200 day moving average is $10.51.
Addex Therapeutics (NASDAQ:ADXN – Get Free Report) last issued its quarterly earnings results on Thursday, June 6th. The company reported ($1.37) earnings per share (EPS) for the quarter. The business had revenue of $0.27 million for the quarter. Addex Therapeutics had a negative return on equity of 364.24% and a negative net margin of 818.50%. Research analysts anticipate that Addex Therapeutics will post -11.8 earnings per share for the current fiscal year.
Institutional Trading of Addex Therapeutics
Addex Therapeutics Company Profile
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Further Reading
- Five stocks we like better than Addex Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- 3 Warren Buffett Stocks to Buy Now
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the NASDAQ Stock Exchange?
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.